Online Only Articles

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy

Department of Informatics, University of Oslo, Oslo, Norway;Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Institute of Pathology, University of Würzburg and Comprehensive Cancer Centre Mainfranken, Germany
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Division of Haematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Division of Haematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden
Department of Oncology, Oslo University Hospital, Oslo, Norway
Department of Informatics, University of Oslo, Oslo, Norway;Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
Division of Haematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden
Institute of Pathology, University of Würzburg and Comprehensive Cancer Centre Mainfranken, Germany
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;Department of Oncology, Oslo University Hospital, Oslo, Norway
Department of Informatics, University of Oslo, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;KG Jebsen Centre for B-Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;Department of Oncology, Oslo University Hospital, Oslo, Norway
Vol. 104 No. 10 (2019): October, 2019 https://doi.org/10.3324/haematol.2018.209080